What are Supernus Pharmaceuticals's profit margins?

Supernus Pharmaceuticals (SUPN) runs a 89.4% gross margin and a -7.8% operating margin, with a -3.7% net margin.

Where do Supernus Pharmaceuticals's ratios come from?

Every ratio is computed from Supernus Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.

Supernus Pharmaceuticals SUPN Ratios & Valuation

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Profitability
Gross margin	89.4%-0.2pp	89.6%+1.0pp	88.6%+0.1pp	88.5%+0.1pp	88.4%+0.2pp
Operating margin	-7.8%+0.9pp	-8.7%-3.2pp	-5.4%-15.1pp	9.6%-1.5pp	11.2%-1.2pp
Net margin	-3.7%+1.6pp	-5.4%-2.6pp	-2.8%-12.5pp	9.7%+0.4pp	9.3%-1.9pp
EBITDA margin	4.8%+0.7pp	4.1%-3.0pp	7.1%-14.7pp	21.8%-1.4pp	23.1%-1.3pp
Returns
Return on equity	-2.8%+0.9pp	-3.7%-1.8pp	-1.9%-8.2pp	6.4%+0.1pp	6.3%-1.2pp
Return on assets	-2%+0.7pp	-2.7%-1.3pp	-1.4%-6.2pp	4.8%+0.1pp	4.7%-0.9pp
Return on invested capital	-6.4%-0.1pp	-6.3%-2.5pp	-3.8%-9.1pp	5.3%-0.1pp	5.4%-1.1pp
Efficiency
Asset turnover	0.5×0.0×	0.5×0.0×	0.5×0.0×	0.5×0.0×	0.5×0.0×
Inventory turnover	2.2×—	——	1.7×+0.3×	1.4×+0.1×	1.2×—
Liquidity
Current ratio	2×+0.1×	1.9×+0.1×	1.8×-0.8×	2.6×+0.1×	2.4×+0.1×
Quick ratio	1.9×+0.1×	1.8×+0.1×	1.7×-0.7×	2.4×+0.2×	2.3×-0.1×
Cash ratio	0.5×+0.1×	0.4×-0.1×	0.5×0.0×	0.5×+0.1×	0.4×+0.2×
Leverage
Debt-to-equity	0×0.0×	0×0.0×	0×0.0×	0×0.0×	0×0.0×
Debt-to-assets	0×0.0×	0×0.0×	0×0.0×	0×0.0×	0×0.0×
Net debt / EBITDA	-3.9×-0.9×	-3×-0.8×	-2.3×-1.5×	-0.8×-0.2×	-0.5×-0.3×
Per Share
Book value per share	$18.68-0.7%	$18.81+1.3%	$18.56-1.2%	$18.78+1.8%	$18.45-0.3%
Valuation
Market capitalization	$2.98B+4.4%	$2.85B+6.3%	$2.68B+51.1%	$1.77B-3.0%	$1.83B-8.5%
Enterprise value	$2.83B+2.5%	$2.76B+7.5%	$2.57B+54.7%	$1.66B-4.8%	$1.74B-11.1%
Price / sales	3.8×-0.1×	4×0.0×	3.9×+1.3×	2.7×-0.1×	2.7×-0.3×
Price / book	2.8×+0.1×	2.7×+0.1×	2.6×+0.9×	1.7×-0.1×	1.8×-0.2×
EV / EBITDA	76.6×-17.7×	94.3×+41.3×	53×+41.6×	11.5×+0.2×	11.3×-0.8×
EV / sales	3.6×-0.2×	3.8×+0.1×	3.8×+1.3×	2.5×-0.1×	2.6×-0.4×
Earnings yield	-1%+0.4pp	-1.4%-0.6pp	-0.7%-4.4pp	3.6%+0.3pp	3.4%-0.3pp

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Supernus Pharmaceuticals.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are Supernus Pharmaceuticals's profit margins?: Supernus Pharmaceuticals (SUPN) runs a 89.4% gross margin and a -7.8% operating margin, with a -3.7% net margin.
Where do Supernus Pharmaceuticals's ratios come from?: Every ratio is computed from Supernus Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.